99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis (Annexin 03)

Advanced Accelerator Applications

Status and phase: Terminated; Phase 2

Conditions: Spondyloarthritis

Treatments: Drug: rhAnnexin V-128

Study type: Interventional

Funder types: Industry

Identifiers

NCT03232580

AAA-Annexin-03

CAAA113A22201 (Other Identifier)

Details and patient eligibility

About

This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.

Overall, it was planned to recruit 20 adults with suspected or confirmed SpA. First, 5 patients were enrolled into a "proof of concept" phase, to assess the imaging potential of 99mTc-rhAnnexin V-128 in terms of imaging quality, disease-lesion radiotracer uptake and medical relevance. Based on these results the Data Monitoring Committee (DMC) was to decide whether to terminate the study or whether to continue and enroll the next 15 planned patients.

Full description

The study was prematurely terminated by the sponsor after the first 5 patients completed the PoC phase based on strategic considerations.

Novartis acquired Advanced Accelerator Applications SA.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

For the first 5 patients enrolled in the POC part:

1. Patients with clinical suspicion or confirmed diagnosis of SpA, based on the ASA criteria with active symptoms including back, hip or buttock pain prior to:

• A change in NSAID therapy or
• A change in non-biologic DMARD or
• A start of non-biologic DMARD.

For the next 15 patients enrolled in the Phase II part:

1. Patients with clinical suspicion or confirmed diagnosis of SpA, based on the ASAS criteria with active symptoms including back, hip or buttock pain prior to:

   • A change in NSAIDs therapy
   • A change in non-biologic DMARD
   • A start of non-biologic DMARD
   • A start of biologic DMARD

   For all patients:

2. Age over 18 years old.

3. Signed Informed Consent Form

Exclusion criteria

1. Pregnancy or lactation
2. Liver impairment (ALT, AST or Bilirubin > 2 ULN) at screening visit or baseline
3. Kidney impairment (serum creatinine > 1.5 mg/dL)
4. History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
5. Known hypersensitivity to the investigational drug or any of its components
6. Contraindication(s) to the MRI procedure (claustrophobia, prosthetic valve, pacemaker, inability to lie still in a supine position)
7. Participation to another clinical trial within 4 weeks before study inclusion except for patients who have participated or who are currently participating in an interventional study without any study drug administration.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

rhAnnexin V-128

Experimental group

Description:

All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.

Treatment:

Drug: rhAnnexin V-128